Share ownership AstraZeneca PLC

AZN

GB0009895292

Pharmaceuticals

Market Closed - London S.E. Other stock markets 10:05:18 09/03/2026 pm IST			5-day change	1st Jan Change
14,442.00 ^GBX	-0.40%		-5.31%	+4.73%

10/03	AstraZeneca and Daiichi Sankyo Enter Global Collaboration to Jointly Develop and Commercialize Enhertu	CI
10/03	Alexion And AstraZeneca Announce Koselugo Approval in Canada for Plexiform Neurofibromas in Adults with Neurofibromatosis Type 1	CI

Share class: AstraZeneca PLC

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	1,55,05,81,134	1,49,80,95,796 ( 96.62 %)	0	96.62 %

Major shareholders: AstraZeneca PLC

Name	Equities	%	Valuation
Wellington Management Co. LLP 4.199 %	6,51,20,892	4.199 %	12 153 M p
Capital Research & Management Co. (World Investors) 4.052 %	6,28,39,170	4.052 %	11 727 M p
Investor AB (Investment Company) 3.326 %	5,15,87,810	3.326 %	9 628 M p
BlackRock Investment Management (UK) Ltd. 3.092 %	4,79,54,078	3.092 %	8 949 M p
The Vanguard Group, Inc. 2.644 %	4,10,01,413	2.644 %	7 652 M p
Norges Bank Investment Management 2.085 %	3,23,31,000	2.085 %	6 034 M p
BlackRock Fund Advisors 1.24 %	1,92,25,203	1.24 %	3 588 M p
Goldman Sachs Asset Management LP 1.112 %	1,72,45,000	1.112 %	3 218 M p
SSgA Funds Management, Inc. 1.091 %	1,69,28,000	1.091 %	3 159 M p
Legal & General Investment Management Ltd. 1.079 %	1,67,38,000	1.079 %	3 124 M p
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Caixa DTVM SA 0.001089 %	1,01,352	0.001089 %	2 M p

Breakdown by shareholder type

Institutional	51.8%
Other	1.32%
Governments	0.07%
Individuals	0.03%
Svenska Handelsbanken AB	0.01%
Wärtsilä Oyj Abp	0.01%
Avolta AG	0.01%
Principal Financial Group, Inc.	0.01%
Unknown	46.74%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	23.04%
United Kingdom	14.5%
Sweden	4.57%
Norway	2.35%
Luxembourg	1.16%
Switzerland	1.06%
Germany	0.98%
France	0.76%
Netherlands	0.71%
Canada	0.67%
Japan	0.67%
Singapore	0.42%
Bahamas	0.34%
South Korea	0.28%
Spain	0.23%
Hong Kong	0.18%
Italy	0.17%
Finland	0.15%
Ireland	0.15%
Australia	0.14%
Denmark	0.14%
Belgium	0.09%
Austria	0.07%
Bermuda	0.06%
Taiwan	0.06%
South Africa	0.05%
Kazakhstan	0.04%
Czech Republic	0.04%
Individuals	0.03%
New Zealand	0.03%
Thailand	0.02%
United Arab Emirates	0.02%
Malaysia	0.02%
Kuwait	0.01%
Cyprus	0.01%
Mexico	0.01%
Brazil	0.01%

Based on 1000 largest holdings

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).

Employees

96,100

Sector

Pharmaceuticals

Calendar

29/04 - Earnings release - Q1 2026

More about the company